Market Overview

Sanofi, Pozen Announce Exclusive License Deal for Commercialization of PA8140/PA32540 Tablets in US

Share:
Related SNY
Carl Icahn's Track Record In Big Pharma
Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market'
Synergy: 3 Scenarios, 1 Choice (Seeking Alpha)
Related POZN
Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Q4 Profit Drops
POZEN And Tribute Announce Plan To Proceed With Merger To Form Aralez Pharmaceuticals, $350 Million Capital Commitment from Deerfield-Led Syndicate

Sanofi US (NYSE: SNY) and POZEN Inc. (NASDAQ: POZN) announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor (PPI), and enteric-coated (EC) aspirin in a single tablet ("PA"), PA8140 and PA32540. Under the terms of the agreement, Sanofi will have exclusive rights to commercialize all PA combinations that contain 325 mg or less of enteric-coated aspirin in the United States. POZEN will receive an upfront payment of $15MM and will be eligible for pre-commercial milestone payments of up to $20MM and other future milestone payments and royalties on product sales.

Posted-In: News FDA

 

Related Articles (POZN + SNY)

View Comments and Join the Discussion!